Reflections on alpha blockade therapy for benign prostatic hyperplasia
1995; Wiley; Volume: 75; Issue: 3 Linguagem: Inglês
10.1111/j.1464-410x.1995.tb07335.x
ISSN1365-2176
Autores Tópico(s)Anesthesia and Pain Management
ResumoBritish Journal of UrologyVolume 75, Issue 3 p. 265-270 Reflections on alpha blockade therapy for benign prostatic hyperplasia M. Caine, M. Caine Hadassah University Hospital, Jerusalem, Israel M. Caine, MS, FRCS, FACS, Professor of Urology, Hadassah University Hospital, Kiryat Hadassah, Israel.Search for more papers by this author M. Caine, M. Caine Hadassah University Hospital, Jerusalem, Israel M. Caine, MS, FRCS, FACS, Professor of Urology, Hadassah University Hospital, Kiryat Hadassah, Israel.Search for more papers by this author First published: March 1995 https://doi.org/10.1111/j.1464-410X.1995.tb07335.xCitations: 11 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48: 255 – 63. 2 Recommendations of the International Consensus Committee. In ATK Cockett, S Khoury, Y Aso et al. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Paris :SCI, 1993; 564. 3 Hieble JP, Caine M, Zalaznik E. In vitro characterisation of the alpha-adrenoceptors in the human prostate. Eur J Pharm 1985; 107: 111 – 7. 4 Hedlund H, Andersson K-E, Larsson B. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol 1985; 134: 1291 – 8. 5 Kondo S, Tashima Y, Morlta T. Quantitative analysis of adrenergic alpha-1 and alpha-2 receptors in human prostatic urethral tissue. Br J Urol 1993; 72: 68 – 73. 6 Gup GI, Shapiro E, Baumann M, Lepor H. Autonomic receptors in human prostate adenomas. J Urol 1990; 143: 179 – 85. 7 James S, Chappie CR, Phillips MI et al. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol 1989; 142: 438 – 44. 8 Kondo S, Morita T, Tsuchiya N, Kawahara T, Tsuchida S. Adrenergic alpha-1 and alpha-2 receptors in three layers of human prostatic urethra. J Urol 1990; 143: 338A (Abst 597). 9 Caine M, Perlberg S, Shapiro A. Phenoxybenzamine for benign prostatic obstruction:review of 200 cases. Urology 1981; 17: 542 – 6. 10 Boreham PF, Braithwaite P, Milewski P, Pearson H. Alpha-adrenergic blockers in prostatism. Br J Surg 1977; 64: 756 – 7. 11 Ruutu ML, Hansson E, Juusela HE et al. Efficacy and side effects of prazosin as a symptomatic treatment of benign prostatic obstruction. Scand J Urol Nephrol 1991; 25: 15 – 19. 12 Chappie CR, Stott M, Abrams PH. Christmas TJ, Milroy EJG. A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol 1992; 70: 285 – 94. 13 Lepor H and The Abbot Terazosin BPH group. Long-term safety and efficacy of terazosin for the treatment of clinical BPH:an interim analysis. J Urol 1993; 149: 324A (Abst. 444). 14 Fawzy A, Sullivan J, Cook M, Gonzalez F. A multicenter sixteen-week double-blind placebo-controlled dose-response study using doxazosin tablets for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension. J Urol 1993; 149: 323A (Abst. 443). 15 Gillenwater JY, Mobley DL. A sixteen week, double-blind, placebo controlled, dose-titration study using doxazosin tablets for the treatment of benign prostatic hyperplasia (BPH) in normotensive males. J Urol 1993; 149: 324A (Abst. 447). 16 Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localisation of mRNA for three distinct alpha-1 adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546 – 51. 17 Smith DJ, Chappie CR, Marshall I et al. Human alpha lC-adrenoceptors:functional characterisation in the human prostate. J Urol 1993; 149: 434A (Abst 887). 18 Lepor H, Rui T, Shapiro E, Forray C, Wetzel J, Gluchowski C. Localization of alpha lc adrenoceptor subtype in the human prostate. J Urol 1994; 151: 381A (Abst. 614). 19 Wall PD. The placebo effect:an unpopular topic. Pain 1992; 51: 1 – 3. 20 Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297 – 307. 21 Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551 – 4. 22 Fabricius PG, MacHannaford J. Placebo-controlled study of Terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. Br J Urol 1992; 70:Suppl 1. 10 – 16. 23 Golomb J, Lindner A, Siegel Y, Korczak D. Variability and circadian changes in home uroflowmetry in patients with benign prostatic hyperplasia compared to normal controls. J Urol 1992; 147: 1044 – 7. 24 Carter PG, Lewis P, Abrams P. Single versus multiple flows in the diagnosis of obstruction. J Urol 1991; 145: 397A (Abst 739). 25 Matzkin H, Van der Zwaag R, Chen Y, Patterson LA, Braf Z, Soloway MS. How reliable is a single measurement of urinary flow in the diagnosis of obstruction in benign prostatic hyperplasia Br J Urol 1993; 72: 181 – 6. 26 Kirby R. Use of two consecutive uroflow readings in assessing prostatic obstruction-experience in a double-blind study of Doxazosin in the treatment of benign prostatic hyperplasia (BPH). J Urol 1994; 151: 269A (Abst. 169). 27 Griffiths CJ, Murray A, Ramsden PD. Accuracy and repeatability of bladder volume measurement using ultrasonic imaging. J Urol 1986; 136: 808 – 12. 28 Kiely EA, Hartnell GG, Gibson RN, Williams G. Measurement of bladder volume by real-time ultrasound. Br J Urol 1987; 60: 33 – 5. 29 Bruskewitz RC, Iverson P, Madsen PO. Value of postvoid residual urine determination in evaluation of prostatism. Urology 1982; 20: 602 – 4. 30 Birch NC, Hurst G, Doyle PT. Serial residual volumes in men with prostatic hypertrophy. Br J Urol 1988; 62: 571 – 5. 31 Caine M, Perlberg S. Dynamics of acute retention in prostatic patient and role of adrenergic receptors. Urology 1977; 9: 399 – 403. 32 Reuther K, Aagaard J. Acute retention of urine due to benign prostatic obstruction treated with alpha-adrenergic blockers. Urol lnt 1984; 39: 114 – 15. 33 Leventhal A, Pfau A. Pharmacological management of post-operative over-distension of the bladder. Surg Gynecol Obstet 1978; 146: 347 – 8. 34 Petersen MS, Collins DN, Selakovich WG, Finkbeiner AE. Post-operative urinary retention associated with total hip and total knee arthroplasties. Clin Orthop Rel Res 1991; 269: 102 – 8. 35 Uson AC, Paez AB, Uson-Jaeger J. The natural history and course of untreated benign prostatic hyperplasia. Eur Urol 1991; 20:Suppl 2 22 – 6. 36 Lepor H, Meretyk S, Knapp-Maloney G. The safety, efficacy and compliance of Terazosin therapy for benign prostatic hyperplasia. J Urol 1992; 147: 1554 – 7. 37 Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P, BPHALF group. Long-term treatment of benign prostatic hyperplasia with Alfuzosin:a 12–18 month assessment. Br J Urol 1993; 72: 615 – 20. 38 Stoner E, Members of the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284 – 94. Citing Literature Volume75, Issue3March 1995Pages 265-270 ReferencesRelatedInformation
Referência(s)